-
Mashup Score: 0Low Disease Activity Linked to Less Radiographic Progression in Patients With PsA Receiving Guselkumab - 1 year(s) ago
Radiographic non-progressors treated with guselkumab achieved patient-reported minimal disease activity criteria of minimal pain and normalized physical function more often than radiographic non-responders.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Low Disease Activity Linked to Less Radiographic Progression in Patients With PsA Receiving Guselkumab - 1 year(s) ago
Radiographic non-progressors treated with guselkumab achieved patient-reported minimal disease activity criteria of minimal pain and normalized physical function more often than radiographic non-responders.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Radiographic non-progressors treated with #guselkumab achieved patient-reported minimal disease activity criteria of minimal pain and normalized physical function more often than radiographic non-responders. https://t.co/NX5UuTmEDj #PsoriaticArthritis
-
-
Mashup Score: 0Selecting the Right Biologic Treatment for Psoriasis Patients - 1 year(s) ago
An American Academy of Dermatology Reading Room selection
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
ICYMI: Researchers investigated the drug survival associated with effectiveness and safety of adalimumab, #ustekinumab, secukinumab, ixekizumab, and #guselkumab in patients with #psoriasis. #AADReadingRoom @AADskin #dermatology Read more: https://t.co/M0lXfSULgl https://t.co/msRoNPpuSq
-
-
Mashup Score: 0Guselkumab’s safety profile consistent regardless TNF-inhibitor use in psoriatic arthritis - 1 year(s) ago
The 2-year safety profile of guselkumab appears consistently favorable across patients with psoriatic arthritis who are either naïve or experienced with TNF inhibitors, according to data published by The Journal of Rheumatology. “Guselkumab, a monoclonal antibody that selectively inhibits interleukin (IL)-23 p19, was the first agent in its class approved for patients with active PsA,”
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
ICYMI: The 2-year safety profile of #guselkumab appears consistently favorable across patients with psoriatic #arthritis who are either naïve or experienced with TNF inhibitors https://t.co/bkm3CKBP9M
-
-
Mashup Score: 0Guselkumab’s safety profile consistent regardless TNF-inhibitor use in psoriatic arthritis - 1 year(s) ago
The 2-year safety profile of guselkumab appears consistently favorable across patients with psoriatic arthritis who are either naïve or experienced with TNF inhibitors, according to data published by The Journal of Rheumatology. “Guselkumab, a monoclonal antibody that selectively inhibits interleukin (IL)-23 p19, was the first agent in its class approved for patients with active PsA,”
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
The 2-year safety profile of #guselkumab appears consistently favorable across patients with psoriatic #arthritis who are either naïve or experienced with TNF inhibitors https://t.co/bkm3CKBP9M
-
-
Mashup Score: 0Guselkumab Delivers Long-Term Improvements in TNF-Naïve, TNF-Experienced Patients With Psoriatic Arthritis - 1 year(s) ago
Guselkumab, an interleukin-23 inhibitor, demonstrated sustained improvements in both TNF-naïve and TNF-experienced patients with psoriatic arthritis.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
New study shows that #guselkumab may provide long-term relief for both TNF-naïve and TNF-experienced patients with psoriatic arthritis, offering hope for those who have been searching for an effective treatment option. https://t.co/OGapEJh6Q2 #PsoriaticArthritis #Rheumatology
-
-
Mashup Score: 0
Patients receiving guselkumab reported significant improvements in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores over 36 months.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
Patients receiving #guselkumab reported significant improvements in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores over 36 months. https://t.co/IXPdvyKQds
-
-
Mashup Score: 0
Patients receiving guselkumab reported significant improvements in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores over 36 months.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Patients receiving #guselkumab reported significant improvements in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores over 36 months. https://t.co/t7Dmerf9e2 #Psoriasis
-
-
Mashup Score: 0Study Suggests Efficacy of Guselkumab in Psoriasis Patients with Inadequate Ustekinumab Response - 1 year(s) ago
New research, comparable with that of the NAVIGATE trial, was conducted and showed strong results for the use of guselkumab for psoriasis patients.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
A new study found that #guselkumab was effective for adult moderate-to-severe #PlaquePsoriasis patients with inadequate responses to ustekinumab. Check out the story here: https://t.co/emDqanLUpt
-
-
Mashup Score: 0Early Response to Guselkumab Linked to Long-Term Improvement in Health-Related QoL in PsA - 1 year(s) ago
DISCOVER-2 is a phase 3, randomized, double-blind, multicenter study assessing the safety and efficacy of subcutaneous guselkumab treatment in biologic-naïve patients with active PsA.
Source: Rheumatology NetworkCategories: Latest Headlines, RheumatologyTweet-
Patients with active #PsoriaticArthritis who had an early response to #guselkumab reported more meaningful, long-term improvement in health-related quality of life (HR-QoL) at week 100. https://t.co/O2frQZbbZV
-
Radiographic non-progressors treated with #guselkumab achieved patient-reported minimal disease activity criteria of minimal pain and normalized physical function more often than radiographic non-responders. https://t.co/OBX7kgtPUa #PsoriaticArthritis